Enzymotec Ltd. (ENZY) Trading -0.8% Higher Following Analyst Upgrade
Enzymotec Ltd. (NASDAQ:ENZY)’s share price traded up 0.8% during trading on Tuesday after Wells Fargo & raised their price target on the stock from $9.50 to $12.00. Wells Fargo & currently has a market perform rating on the stock. Enzymotec traded as high as $11.85 and last traded at $11.75. 980,046 shares traded hands during trading, an increase of 673% from the average session volume of 126,818 shares. The stock had previously closed at $11.85.
Several other equities analysts have also recently commented on ENZY. ValuEngine raised shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $11.50 price target on shares of Enzymotec in a research report on Thursday, October 19th. Finally, Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Four equities research analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and a consensus price target of $11.75.
Several hedge funds have recently modified their holdings of the company. Osborn Williams & Donohoe LLC bought a new position in shares of Enzymotec during the third quarter worth about $137,000. State Street Corp lifted its position in shares of Enzymotec by 1.8% during the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 380 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Enzymotec during the second quarter worth about $2,350,000. 27.20% of the stock is currently owned by institutional investors and hedge funds.
Enzymotec (NASDAQ:ENZY) last posted its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.15). The company had revenue of $13.00 million during the quarter, compared to analyst estimates of $12.78 million. Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.04 earnings per share.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.